This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Meridian Bioscience Reports Third Quarter And Nine Months Operating Results, Declares Regular Cash Dividend, And Revises Fiscal 2012 Guidance

1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impact of non-routine costs related to consolidating the Maine operations and reorganizing our Sales and Marketing Leadership; and

2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.

We have provided reconciliations of net earnings, basic earnings per share and diluted earnings per share, with and without the effects of the plant consolidation and leadership reorganization costs noted above, in the tables below for the three and nine month periods ended June 30, 2012.

       
THIRD QUARTER AND NINE MONTH YEAR TO DATE

GAAP TO NON-GAAP RECONCILIATION TABLES

(In Thousands, Except per Share Data)
 
Three Months Nine Months
Ended June 30, Ended June 30,
2012   2011 2012   2011
Net Earnings -
U.S. GAAP basis $ 8,594 $ 6,836 $ 24,798 $ 20,121
Facility Consolidation costs 238 - 659 -
Sales & Marketing Leadership Reorganization   -   -   -   872
Adjusted Earnings $ 8,832 $ 6,836 $ 25,457 $ 20,993
 
Net Earnings per Basic Common Share -
U.S. GAAP basis $ 0.21 $ 0.17 $ 0.60 $ 0.49
Facility Consolidation costs 0.01 - 0.02 -
Sales & Marketing Leadership Reorganization   -   -   -   0.02
Adjusted Basic EPS $ 0.21* $ 0.17 $ 0.62 $ 0.52*
 
Net Earnings per Diluted Common Share -
U.S. GAAP basis $ 0.21 $ 0.17 $ 0.60 $ 0.49
Facility Consolidation costs 0.01 - 0.02 -
Sales & Marketing Leadership Reorganization   -   -   -   0.02
Adjusted Diluted EPS $ 0.21* $ 0.17 $ 0.61 * $ 0.51
 
*Does not sum to total due to rounding.
 

FORWARD LOOKING STATEMENTS

4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs